Member Info for BuenaVista

A note to Roger65. You are clearly an impatient investor. As I see it you have two options.

1. Take your money down the bookies and get instant gratification on a win or lose. Or, if online is your thing, try one of those fantastically fun bingo sites.

2. Take a gamblers anonymous course and put your money in the Post Office.

Previous post was addressed to MB53.

------

Avacta are recruiting a medicinal chemist, seemly to make (and so patent) a collection of follow-on pre|CISION prodrugs. Those would clearly be for licensing out.

I think Avacta is playing this both ways; maximise the value of pre|CISION by intending to take AVA6000 to market and license out follow-on candidates which, together, will provide revenue to take AVA3996 through clinical trials to market. As an idea of how long that process will take for AVA3996, look at Takeda's follow-on multiple myeloma candidate, modakafusp alfa, to see their timelines and the treatment regimens being studied in just early stage (Phase 1/2) clinical trials:
https://clinicaltrials.gov/ct2/results?term=Modakafusp+alfa&cond=Multiple+Myeloma

And all the time the value within Avacta will be increasingly demonstrated for takeover suitors to see.

That would depend on whether Takeda regarded AVA2727D as being superior to modakafusp alfa.

Two different markets.

As hanoihank says, Velcade market is blood cancer. As no FAP there, it is not a market for AVA3996. Velcade can't be used for solid tumours because the toxic effect outweighs the therapeutic effect. That is what AS stressed.

The market for AVA3996 is FAP-rich solid tumours. AVA3996 would be a first in class anticancer for this market. That's to say, the market is wide open for an effective tumour-agnostic therapy.

So both AVA6000 and AVA3996 are, for different reasons, likely blockbusters - assuming AVA3996 proves to be safe, tolerated and efficacious.

So Ade1234, Daz9643 and Garonne are all the same person, Clown101. Any more?

If Clown101 can't get the pot stirred it just calls in one of its other accounts.

Quite frankly, anyone who reads this Clown101's daily drivel and hasn't sussed that someone (or in this case what appears to be several people) constantly knocking the company can't possibly be invested in the company and then foolishly gets panicked into selling is... well, a fool.

Personally I have no problem with Clown101 constantly knocking the company and trying to drive the price down. All the more opportunity to acquire more shares at knockdown prices and I believe the company will come good in the end. A bit sad for it though, to have one's life defined as a scumbag on an online bulletin board.

So Ade1234 and Daz9643 are two accounts of the same person.

Clearly a person lacking any great imagination.

A clown one might say.

Clown101

Valuation of £587m, equivalent to 221p per share, has been in place since December. They are currently using a shares number of 269.87m.

The Trinity update has no impact on the actual share price, which has been way below Trinity's valuation for a long time.

https://www.trinitydelta.org/companies/avacta/

RD, hence the current vacancy for a Principal/Senior Medicinal Chemist:

"Innovation and collaboration are key for Avacta, and we are looking for an experienced Medicinal Chemist to be responsible for the day-to-day chemistry support of our pre|CISION™ platform, designing and overseeing the synthesis of novel compounds for drug discovery programs. Reporting to Dr Francis Wilson, VP Chemistry, and working with outsourced chemistry, you will assist in the building of an internal chemistry infrastructure to support a growing project portfolio."
https://avacta.com/wp-content/uploads/2023/04/Principal-Senior-Medicinal-Chemist-job-spec-FINAL.pdf

Avacta gearing up to synthesise and patent a whole series of pre|CISION prodrugs for licensing out.

Getting AVA6000 onto the market plus income from licensed pre|CISION assets should fund AVA3996's progress through the full clinical trial process and should make Avacta a very cash-rich company* if not taken over. Only caveat is that AVA3996 is a NCE so will need to go through all phases of clinical trials and may fail on safety, tolerability or efficacy during that process but, if targetting to the TME is as good as the early preclinical data suggest, then that possibility is small and, as a first in class targetted solid tumour agnostic chemotherapy the market is wide open to it.

* No prizes for guessing where some of that cash will be earmarked for!

"Trinity Delta view: FY22 results reveal the financial, operational, and strategic progress made across both Avacta’s Therapeutics and Diagnostics divisions. The pre|CISION platform underpins the near- and medium-term prospects of its Therapeutics business, with emerging data from lead asset AVA6000 effectively validating the pre|CISION platform’s tumour targeting potential and providing the blueprint for an extensive pipeline of related products. AVA3996, the second pre|CISION asset, could enter the clinic within 12 months. The Diagnostics M&A-led growth strategy, seeded with the Launch Diagnostics acquisition, and complemented by internal capabilities and the proprietary Affimer platform, should create a self-sustaining Diagnostics business. Our current Avacta valuation is £587m, equivalent to 221p per share."
Dated 25 April 2023.

Avacta's RNS of 21 April stated that, as of 25 April, there will be 275,348,077 shares following the admission of the latest tranche of Heights payment shares.

If Trinity Delta's valuation of Avacta is £587m, then the equivalent would be 213.2p per share.

Didn't hit a nerve at all. Was just wondering how old you are.

What a stupid thread. Why are you doing this?

OK. Specifically Affimers. What's been happening there? Lots of publications from academia - Leeds Uni and others - showing how good they are for this and that and yet... no big companies seem to want to sign a partnership deal to develop them for therapeutic use. Why's that? A big deal or two there could fill the coffers to overflowing. Maybe there is rationality there somewhere - Affimers not worth bothering with for them when the big prize is a pre|CISION partnership or company buy out - but the IP just seems a wasting asset at the moment.

Careful your knee doesn't break your jaw MrR.

A bit nervous about this investment you don't really understand are you? lol

In the real world critcism is allowed.

Projecting cash burn is pointless unless it is known what the cash will be spent on and what revenue(s) will be received.

What can be guaranteed is that this year and next year and the year after will not be like the past year, so no point forward projecting based on what's happened. It's what will happen that is important and, frankly, we (us investors and to a large part Avacta as well) don't know.

What would increase cash burn are more trials for AVA6000 (for example Phase 2 for STS and the start of breast and ovarian cancer trials); production, marketing, sales and distribution for AVA6000; Phase 1 dose finding studies for AVA3996; more intense Affimer preclinical work, including TMAC; and various unknowns.

What would decrease the cash burn are revenue streams and funding options as set out in the prelims.

I'm getting increasingly disheartened that Avacta have not managed to sign any partnership of any sort for any of their tech platforms with any major pharma company. That really needs to change if the pre|CISION platform beyond AVA6000 and any Affimer platform candidates are to make it to market barring an exclusivity extension for AVA3996.

Ade1234 is a nothing. No morals, no honour, no integrity, no shame. Just a word salad.

Do you have a life outside AFC/LSE?

Ignore the trolls and their lies.

"I also really like this approach to change the form of the larger output towers, into a more traditional looking generator, shows we are listening to the customer and giving them what they want not what we think they need."

Absolutely spot on AFlC. Listening to your customer base and providing products that will satisfy their needs is the hallmark of a quality company that will be an industry leader. AFC have shown this in spades throughout the development process and it has obviously taken time to go through an iterative process with such a complex piece of equipment and new, propriety technology. That they are now marrying customer-orientated products with reduced-cost mass production means we are getting very close satisfying a mass market. I'm very, very impressed with AFC. A quality company.

That haggis is a right idiot

Just remember that trading trolls only bash good companies.